{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:50Z","timestamp":1792783490734,"version":"4.5.0"},"reference-count":191,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T00:00:00Z","timestamp":1660435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T00:00:00Z","timestamp":1660435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Parenteral Drug Association, India Chapter"},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s13346-022-01223-5","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T20:03:26Z","timestamp":1660421006000},"page":"433-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["An expanding horizon of complex injectable products: development and regulatory considerations"],"prefix":"10.1007","volume":"13","author":[{"given":"Kanan","family":"Panchal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Katke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanat Kumar","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithun","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelesh Kumar","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-0368","authenticated-orcid":false,"given":"Akash","family":"Chaurasiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,14]]},"reference":[{"key":"1223_CR1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jconrel.2021.06.017","volume":"336","author":"MN O\u2019Brien","year":"2021","unstructured":"O\u2019Brien MN, Jiang W, Wang Y, Loffredo DM. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021;336:144\u201358. https:\/\/doi.org\/10.1016\/j.jconrel.2021.06.017.","journal-title":"J Control Release"},{"key":"1223_CR2","unstructured":"IQVIA (Human Data Science CompanyTM). Complex generics: charting a new path. Published online 2016. https:\/\/www.iqvia.com\/-\/media\/library\/white-papers\/complex-generics-charting-a-new-path.pdf."},{"issue":"4","key":"1223_CR3","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/cpt.1364","volume":"105","author":"RA Lionberger","year":"2019","unstructured":"Lionberger RA. Innovation for generic drugs: science and research under the Generic Drug User Fee Amendments of 2012. Clin Pharmacol Ther. 2019;105(4):878\u201385. https:\/\/doi.org\/10.1002\/cpt.1364.","journal-title":"Clin Pharmacol Ther"},{"key":"1223_CR4","unstructured":"Upcoming Product-Specific Guidances for Complex Generic Drug Product Development. USFDA.\u00a0https:\/\/www.fda.gov\/drugs\/guidances-drugs\/upcoming-product-specific-guidances-complex-generic-drug-product-development. Accessed 30 Sept\u00a02021."},{"issue":"6","key":"1223_CR5","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1208\/s12248-015-9814-9","volume":"17","author":"H Wen","year":"2015","unstructured":"Wen H, Jung H, Li X. Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges. AAPS J. 2015;17(6):1327\u201340. https:\/\/doi.org\/10.1208\/s12248-015-9814-9.","journal-title":"AAPS J"},{"key":"1223_CR6","doi-asserted-by":"publisher","first-page":"7291","DOI":"10.2147\/IJN.S146315","volume":"12","author":"FU Din","year":"2017","unstructured":"Din FU, Aman W, Ullah I, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 2017;12:7291\u2013309. https:\/\/doi.org\/10.2147\/IJN.S146315.","journal-title":"Int J Nanomedicine"},{"key":"1223_CR7","doi-asserted-by":"publisher","unstructured":"Lombardo D, Kiselev MA, Caccamo MT. Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine. Fratoddi I, ed. J Nanomater. 2019;3702518. https:\/\/doi.org\/10.1155\/2019\/3702518.","DOI":"10.1155\/2019\/3702518"},{"issue":"1","key":"1223_CR8","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1038\/s41467-019-12141-5","volume":"10","author":"SR Benhabbour","year":"2019","unstructured":"Benhabbour SR, Kovarova M, Jones C, et al. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery. Nat Commun. 2019;10(1):4324. https:\/\/doi.org\/10.1038\/s41467-019-12141-5.","journal-title":"Nat Commun"},{"key":"1223_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fbioe.2020.00127","volume":"8","author":"S Yadav","year":"2020","unstructured":"Yadav S, Sharma AK, Kumar P. Nanoscale self-assembly for therapeutic delivery. Front Bioeng Biotechnol. 2020;8:127. https:\/\/doi.org\/10.3389\/fbioe.2020.00127.","journal-title":"Front Bioeng Biotechnol"},{"issue":"2","key":"1223_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil\u00ae\u2013the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020.","journal-title":"J Control Release"},{"key":"1223_CR11","unstructured":"Haldol\u00ae Decanoate - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/018701s054lbl.pdf. Accessed 30 Sept\u00a02021."},{"issue":"5","key":"1223_CR12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s43441-020-00114-6","volume":"54","author":"S Lunawat","year":"2020","unstructured":"Lunawat S, Bhat K. Complex generic products: insight of current regulatory frameworks in US, EU and Canada and the need of harmonisation. Ther Innov Regul Sci. 2020;54(5):991\u20131000. https:\/\/doi.org\/10.1007\/s43441-020-00114-6.","journal-title":"Ther Innov Regul Sci"},{"key":"1223_CR13","unstructured":"USFDA. Introduction to complex products and FDA considerations. https:\/\/www.fda.gov\/media\/108937\/download. Accessed 4 May\u00a02022"},{"key":"1223_CR14","unstructured":"Copaxone\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/020622s110lbl.pdf. Accessed 30 Sept\u00a02021.\u00a0"},{"key":"1223_CR15","unstructured":"EpiPen - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/019430Orig1s091lbl.pdf.\u00a0Accessed 30 Sept 2021.\u00a0"},{"key":"1223_CR16","unstructured":"FerahemeTM - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022180lbl.pdf. Accessed 30 Sept\u00a02021.\u00a0"},{"key":"1223_CR17","unstructured":"ForteoTM - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/21318_forteo_lbl.pdf.\u00a0Accessed 30 Sept 2021.\u00a0"},{"key":"1223_CR18","unstructured":"Injectafer\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/203565s000lbl.pdf.\u00a0Accessed 30 Sept 2021.\u00a0"},{"key":"1223_CR19","unstructured":"Saxenda - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206321Orig1s000lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR20","unstructured":"Somatuline\u00ae Depot - Package Insert. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022074s024lbl.pdf. Accessed 30 Sept\u00a02021.\u00a0"},{"key":"1223_CR21","unstructured":"Sublocade\u00ae - Package Insert. USFDA. \u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/209819s018lbl.pdf. Accessed 30 Sept\u00a02021."},{"key":"1223_CR22","unstructured":"Tymlos\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208743lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR23","unstructured":"Venofer\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021135Orig1s037lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR24","unstructured":"Victoza - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022341s036lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR25","unstructured":"Advate\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.fda.gov\/media\/70008\/download.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR26","unstructured":"Eligard\u00ae - Package Insert. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/21343lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR27","unstructured":"Vfend\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021266s050,021267s060,021630s039lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR28","unstructured":"Abraxane\u00ae - Package Insert. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/021660lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR29","unstructured":"Aristada - Package Insert. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/207533s017,209830s005lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR30","unstructured":"Invega HafyeraTM - Package Insert. Janssen. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/INVEGA+HAFYERA-pi.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR31","unstructured":"Invega Sustena\u00ae - Package Insert. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022264s023lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR32","unstructured":"Invega Trinza\u00ae - Package Insert. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/207946s009lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR33","unstructured":"Trelstar\u00ae - Package Insert. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020715s040,021288s035,022427s015lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR34","unstructured":"Bydureon\u00ae - Package Insert. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022200s031lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR35","unstructured":"Cabenuva\u00ae - Package Insert. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212888s000lbl.pdf. Accessed 4 May\u00a02022.\u00a0"},{"key":"1223_CR36","unstructured":"Lupaneta\u00ae - Package Insert. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/203696s001lbl.pdf. Accessed 30 Sept\u00a02021.\u00a0"},{"key":"1223_CR37","unstructured":"Lupron Depot\u00ae - Package Insert. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020517s042,019732s044lbl.pdf. Accessed 30 Sept\u00a02021.\u00a0"},{"key":"1223_CR38","unstructured":"Risperdal Costa\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020272Orig1s083,020588Orig1s071,021444Orig1s057,021346Orig1s061lbl.pdf#page=60. Accessed 30 Sept\u00a02021."},{"key":"1223_CR39","unstructured":"Sandostatin LAR\u00ae Depot - Package Insert. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021008s041lbl.pdf. Accessed 30 Sept\u00a02021."},{"key":"1223_CR40","unstructured":"Signifor\u00ae LAR - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/203255s008lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR41","unstructured":"Vivitrol\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021897s052lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR42","unstructured":"Ambisome\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/050740Orig1s031lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR43","unstructured":"Depocyt\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/1999\/21041lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR44","unstructured":"Depodur\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021671s019lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR45","unstructured":"Doxil\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/050718s055lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR46","unstructured":"Exparel\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022496s000lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR47","unstructured":"OnivydeTM - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207793lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR48","unstructured":"Marquibo\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202497s000lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR49","unstructured":"Cinvanti\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209296s004lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR50","unstructured":"Cleviprex - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022156s007lbl.pdf. Accessed 4 July 2021,\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR51","unstructured":"Diprivan\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/019627Orig1s072lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR52","unstructured":"Zoladex\u00ae - Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/019726s059,020578s037lbl.pdf.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR53","unstructured":"Introduction to Complex Products and FDA Considerations. USFDA.\u00a0https:\/\/www.fda.gov\/media\/108937\/download. Accessed 30 Sept 2021."},{"key":"1223_CR54","unstructured":"Newly approved complex drug products and potential challenges to generic drug development. USFDA.\u00a0https:\/\/www.fda.gov\/media\/137513\/download. Accessed 30 Sept\u00a02021."},{"key":"1223_CR55","unstructured":"What are complex drug products and why should you care?. Health CDMO Division. https:\/\/lubrizolcdmo.com\/blog\/what-are-complex-drug-products-and-why-should-you-care\/.\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR56","unstructured":"Guidelines needed for follow-on versions of NBCDs. GABI. https:\/\/www.gabionline.net\/Reports\/Guidelines-needed-for-follow-on-versions-of-NBCDs.\u00a0\u00a0Accessed 30 Sept 2021."},{"key":"1223_CR57","doi-asserted-by":"publisher","unstructured":"Hacker DL, Wurm FM. 2.29 - recombinant technology. In: Moo-Young MBT-CB (Second E, ed. Academic Press.\u00a02011;401\u2013406. https:\/\/doi.org\/10.1016\/B978-0-08-088504-9.00120-3.","DOI":"10.1016\/B978-0-08-088504-9.00120-3"},{"key":"1223_CR58","doi-asserted-by":"publisher","unstructured":"Nambisan P. Chapter 9 - ensuring safety in biotechnology. In: Nambisan Safety and Intellectual Property Rights Issues in Biotechnology PBT-AI to E, ed. Academic Press.\u00a02017;211\u2013232. https:\/\/doi.org\/10.1016\/B978-0-12-809231-6.00009-0.","DOI":"10.1016\/B978-0-12-809231-6.00009-0"},{"key":"1223_CR59","doi-asserted-by":"publisher","unstructured":"Shah NJ. Recombinant DNA technology BT - introduction to basics of pharmacology and toxicology: volume 1: General and Molecular Pharmacology: Principles of Drug Action. In: Raj GM, Raveendran R, eds. Springer Singapore.\u00a02019;413\u2013417. https:\/\/doi.org\/10.1007\/978-981-32-9779-1_34.","DOI":"10.1007\/978-981-32-9779-1_34"},{"key":"1223_CR60","unstructured":"Demonstrating Complex API Sameness. USFDA.\u00a0https:\/\/www.fda.gov\/media\/108970\/download.\u00a0 Accessed 30 Sept\u00a02021."},{"issue":"10","key":"1223_CR61","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","volume":"26","author":"JL Lau","year":"2018","unstructured":"Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700\u20137. https:\/\/doi.org\/10.1016\/j.bmc.2017.06.052.","journal-title":"Bioorg Med Chem"},{"key":"1223_CR62","unstructured":"Glatiramer acetate - PubChem. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Glatiramer-acetate. Accessed 30 Sep\u00a02021.\u00a0"},{"key":"1223_CR63","unstructured":"Development of enhanced analytical tools for evaluation of complex generic products. USFDA.\u00a0https:\/\/www.fda.gov\/media\/125186\/download. Accessed 30 Sep 2021."},{"key":"1223_CR64","unstructured":"AveedTM-Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022219s000lbl.pdf. Accessed 4 May\u00a02022."},{"key":"1223_CR65","unstructured":"Humulin R- Package Insert. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/018780s175s176lbl.pdf.\u00a0 Accessed 4 May\u00a02022.\u00a0"},{"key":"1223_CR66","doi-asserted-by":"publisher","unstructured":"Reynolds T, de Zafra C, Kim A, Gelzleichter TR. Chapter 1 - overview of biopharmaceuticals and comparison with small-molecule drug development. In: Plitnick LM, Herzyk Biosimilars, Vaccines and Specialty Biologics DJBT-ND of NB, eds. Academic Press.\u00a02013;3\u201333. https:\/\/doi.org\/10.1016\/B978-0-12-394810-6.00001-0.","DOI":"10.1016\/B978-0-12-394810-6.00001-0"},{"key":"1223_CR67","unstructured":"Pegasys\u00ae- Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103964s5275lbl.pdf. Accessed 4 May\u00a02022."},{"key":"1223_CR68","unstructured":"Comirnaty\u00ae- Package Insert .USFDA.\u00a0\u00a0https:\/\/www.fda.gov\/media\/151707\/download.\u00a0 Accessed 4 May\u00a02022."},{"key":"1223_CR69","unstructured":"Iron Sucrose \u2013 PSG. USFDA.Iron Sucrose \u2013 PSG. USFDA. \u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Iron_sucrose_inj_21135_RV11-13.pdf. Accessed 30 Sep\u00a02021."},{"issue":"15","key":"1223_CR70","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.2165\/11209880-000000000-00000","volume":"72","author":"PL McCormack","year":"2012","unstructured":"McCormack PL. Ferumoxytol Drugs. 2012;72(15):2013\u201322. https:\/\/doi.org\/10.2165\/11209880-000000000-00000.","journal-title":"Ferumoxytol Drugs"},{"key":"1223_CR71","unstructured":"Ferric carboxymaltose - DrugBank.\u00a0https:\/\/go.drugbank.com\/drugs\/DB08917. Accessed 30 Sep\u00a02021."},{"issue":"8","key":"1223_CR72","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1021\/ic503043h","volume":"54","author":"MR Anneser","year":"2015","unstructured":"Anneser MR, Haslinger S, P\u00f6thig A, Cokoja M, Basset J-M, K\u00fchn FE. Synthesis and Characterization of an iron complex bearing a cyclic tetra-N-heterocyclic carbene ligand: an artifical heme analogue? Inorg Chem. 2015;54(8):3797\u2013804. https:\/\/doi.org\/10.1021\/ic503043h.","journal-title":"Inorg Chem"},{"issue":"5","key":"1223_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2019.08.006","volume":"35","author":"V Bayer","year":"2019","unstructured":"Bayer V. An overview of monoclonal antibodies. Semin Oncol Nurs. 2019;35(5): 150927. https:\/\/doi.org\/10.1016\/j.soncn.2019.08.006.","journal-title":"Semin Oncol Nurs"},{"key":"1223_CR74","unstructured":"Kimmtrak\u00ae Package Insert .USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761228s000lbl.pdf. Accessed 4 May\u00a02022."},{"key":"1223_CR75","unstructured":"Cinqair\u00ae Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761033lbl.pdf. Accessed 4 May\u00a02022."},{"key":"1223_CR76","unstructured":"Fuzeon\u00ae Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021481s033lbl.pdf. Accessed 4 May\u00a02022."},{"key":"1223_CR77","unstructured":"Vancocin\u00ae Package Insert. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/050606s039lbl.pdf%0A. Accessed 4 May\u00a02022."},{"issue":"1","key":"1223_CR78","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ijpharm.2018.05.048","volume":"546","author":"P Kozarewicz","year":"2018","unstructured":"Kozarewicz P, Loftsson T. Novel excipients \u2013 regulatory challenges and perspectives \u2013 The EU insight. Int J Pharm. 2018;546(1):176\u20139. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.05.048.","journal-title":"Int J Pharm"},{"issue":"2","key":"1223_CR79","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/2231-4040.82950","volume":"2","author":"V Patel","year":"2011","unstructured":"Patel V, Agrawal Y. Nanosuspension: an approach to enhance solubility of drugs. J Adv Pharm Technol Res. 2011;2(2):81\u20137. https:\/\/doi.org\/10.4103\/2231-4040.82950.","journal-title":"J Adv Pharm Technol Res"},{"issue":"5","key":"1223_CR80","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s11095-010-0309-1","volume":"28","author":"N Anton","year":"2011","unstructured":"Anton N, Vandamme TF. Nano-emulsions and micro-emulsions: clarifications of the Critical Differences. Pharm Res. 2011;28(5):978\u201385. https:\/\/doi.org\/10.1007\/s11095-010-0309-1.","journal-title":"Pharm Res"},{"issue":"12","key":"1223_CR81","doi-asserted-by":"publisher","first-page":"12111","DOI":"10.1021\/acsnano.7b05100","volume":"11","author":"E Zdrali","year":"2017","unstructured":"Zdrali E, Chen Y, Okur HI, Wilkins DM, Roke S. The molecular mechanism of nanodroplet stability. ACS Nano. 2017;11(12):12111\u201320. https:\/\/doi.org\/10.1021\/acsnano.7b05100.","journal-title":"ACS Nano"},{"key":"1223_CR82","unstructured":"Patel M, Patel S, Patel N, Patel M. A self-microemulsifying drug delivery system (SMEDDS). Int J Pharm Sci Rev Res. 2010;4."},{"key":"1223_CR83","doi-asserted-by":"publisher","unstructured":"Suhail M, Janakiraman AK, Khan A, Naeem A, Badshah SF.\u00a0Surfactants and their role in pharmaceutical product development: an overview. J Pharm Pharm. 2019;6(2):72\u201382. https:\/\/doi.org\/10.15436\/2377-1313.19.2601.","DOI":"10.15436\/2377-1313.19.2601"},{"key":"1223_CR84","doi-asserted-by":"publisher","unstructured":"P.C. Hiemenz RR. No Title. In: Principles of Colloid and Surface Chemistry. Marcel Decker, New York; 1997. https:\/\/doi.org\/10.1201\/9781315274287.","DOI":"10.1201\/9781315274287"},{"issue":"1","key":"1223_CR85","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.colsurfa.2011.05.043","volume":"384","author":"W Zhu","year":"2011","unstructured":"Zhu W, Sabatino P, Govoreanu R, Verbruggen K, Martins JC, Van der Meeren P. Preferential adsorption of polysorbate 20 molecular species in aqueous paliperidone palmitate suspensions. Colloids Surfaces A Physicochem Eng Asp. 2011;384(1):691\u20137. https:\/\/doi.org\/10.1016\/j.colsurfa.2011.05.043.","journal-title":"Colloids Surfaces A Physicochem Eng Asp"},{"issue":"9","key":"1223_CR86","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1021\/acsomega.9b03523","volume":"5","author":"S Pandit","year":"2020","unstructured":"Pandit S, Roy S, Pillai J, Banerjee S. Formulation and intracellular trafficking of lipid\u2013drug conjugate nanoparticles containing a hydrophilic antitubercular drug for improved intracellular delivery to human macrophages. ACS Omega. 2020;5(9):4433\u201348. https:\/\/doi.org\/10.1021\/acsomega.9b03523.","journal-title":"ACS Omega"},{"issue":"9","key":"1223_CR87","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/ejlt.201400219","volume":"116","author":"P van Hoogevest","year":"2014","unstructured":"van Hoogevest P, Wendel A. The use of natural and synthetic phospholipids as pharmaceutical excipients. Eur J Lipid Sci Technol. 2014;116(9):1088\u2013107. https:\/\/doi.org\/10.1002\/ejlt.201400219.","journal-title":"Eur J Lipid Sci Technol"},{"issue":"6","key":"1223_CR88","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.addr.2007.09.010","volume":"60","author":"M-L Chen","year":"2008","unstructured":"Chen M-L. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Adv Drug Deliv Rev. 2008;60(6):768\u201377. https:\/\/doi.org\/10.1016\/j.addr.2007.09.010.","journal-title":"Adv Drug Deliv Rev"},{"key":"1223_CR89","doi-asserted-by":"crossref","unstructured":"Kaur G, Singh D, Brar V. Roles of polymer in drug delivery. J Drug Deliv Ther. 2014;4(3):32\u201336.","DOI":"10.22270\/jddt.v4i3.826"},{"issue":"34","key":"1223_CR90","doi-asserted-by":"publisher","first-page":"8848","DOI":"10.1016\/j.biomaterials.2012.08.042","volume":"33","author":"W Park","year":"2012","unstructured":"Park W, Kim D, Kang HC, Bae YH, Na K. Multi-arm histidine copolymer for controlled release of insulin from poly(lactide-co-glycolide) microsphere. Biomaterials. 2012;33(34):8848\u201357. https:\/\/doi.org\/10.1016\/j.biomaterials.2012.08.042.","journal-title":"Biomaterials"},{"issue":"11","key":"1223_CR91","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1021\/acs.molpharmaceut.0c00619","volume":"17","author":"A Beig","year":"2020","unstructured":"Beig A, Feng L, Walker J, et al. Physical\u2013chemical characterization of octreotide encapsulated in commercial glucose-star PLGA microspheres. Mol Pharm. 2020;17(11):4141\u201351. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00619.","journal-title":"Mol Pharm"},{"issue":"9","key":"1223_CR92","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.progpolymsci.2009.04.006","volume":"34","author":"G Lapienis","year":"2009","unstructured":"Lapienis G. Star-shaped polymers having PEO arms. Prog Polym Sci. 2009;34(9):852\u201392. https:\/\/doi.org\/10.1016\/j.progpolymsci.2009.04.006.","journal-title":"Prog Polym Sci"},{"key":"1223_CR93","doi-asserted-by":"publisher","unstructured":"Cao J, Zhai S, Li C, He B, Lai Y, Chen Y, Luo X, Gu Z. Novel pH-sensitive micelles generated by star-shape copolymers containing zwitterionic sulfobetaine for efficient cellular internalization. J Biomed Nanotechnol. 2013;9:1847\u20131861. https:\/\/doi.org\/10.1166\/jbn.2013.1686.","DOI":"10.1166\/jbn.2013.1686"},{"key":"1223_CR94","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-chembioeng-073009-100847","volume":"1","author":"WB Liechty","year":"2010","unstructured":"Liechty WB, Kryscio DR, Slaughter BV, Peppas NA. Polymers for drug delivery systems. Annu Rev Chem Biomol Eng. 2010;1:149\u201373. https:\/\/doi.org\/10.1146\/annurev-chembioeng-073009-100847.","journal-title":"Annu Rev Chem Biomol Eng"},{"key":"1223_CR95","doi-asserted-by":"publisher","unstructured":"Garti N, Lutz R. Chapter 14 - Recent progress in double emulsions. In: Petsev DNBT-IS and T, ed. Emulsions: Structure Stability and Interactions. Vol 4. Elsevier; 2004:557\u2013605. doi:https:\/\/doi.org\/10.1016\/S1573-4285(04)80016-4.","DOI":"10.1016\/S1573-4285(04)80016-4"},{"issue":"10","key":"1223_CR96","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1080\/03639045.2018.1483392","volume":"44","author":"BM Rayaprolu","year":"2018","unstructured":"Rayaprolu BM, Strawser JJ, Anyarambhatla G. Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics. Drug Dev Ind Pharm. 2018;44(10):1565\u201371. https:\/\/doi.org\/10.1080\/03639045.2018.1483392.","journal-title":"Drug Dev Ind Pharm"},{"key":"1223_CR97","unstructured":"Vfend - Scientific Discussion. EMA.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/vfend-epar-scientific-discussion_en.pdf. Accessed 30 Sept\u00a02021.\u00a0"},{"key":"1223_CR98","unstructured":"OptiMark - Scientific Discussion. EMA.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/optimark-epar-scientific-discussion_en.pdf. Accessed 30 Sept\u00a02021.\u00a0"},{"key":"1223_CR99","unstructured":"The Challenges of Complex Generics; Drug Delivery Experts White Paper, September 2019. http:\/\/drugdeliveryexperts.com\/wp-content\/uploads\/2015\/03\/DDE-Whitepaper-Complex-Generics.pdf. Accessed 30 Sept\u00a02021."},{"key":"1223_CR100","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40005-019-00449-9","volume":"49","author":"WY Lee","year":"2019","unstructured":"Lee WY, Asadujjaman M, Jee J-P. Long acting injectable formulations: the state of the arts and challenges of poly(lactic-co-glycolic acid) microsphere, hydrogel, organogel and liquid crystal. J Pharm Investig. 2019;49:459\u201376.","journal-title":"J Pharm Investig"},{"issue":"2","key":"1223_CR101","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ajps.2013.07.011","volume":"8","author":"M-R Toh","year":"2013","unstructured":"Toh M-R, Chiu GNC. Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing. Asian J Pharm Sci. 2013;8(2):88\u201395. https:\/\/doi.org\/10.1016\/j.ajps.2013.07.011.","journal-title":"Asian J Pharm Sci"},{"issue":"8","key":"1223_CR102","first-page":"1576","volume":"46","author":"MJ Ostro","year":"1989","unstructured":"Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm. 1989;46(8):1576\u201387.","journal-title":"Am J Hosp Pharm"},{"issue":"1","key":"1223_CR103","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ijpharm.2018.06.037","volume":"547","author":"S Peretz Damari","year":"2018","unstructured":"Peretz Damari S, Shamrakov D, Varenik M, et al. Practical aspects in size and morphology characterization of drug-loaded nano-liposomes. Int J Pharm. 2018;547(1):648\u201355. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.06.037.","journal-title":"Int J Pharm"},{"issue":"20","key":"1223_CR104","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1021\/la960218s","volume":"12","author":"MS Spector","year":"1996","unstructured":"Spector MS, Zasadzinski JA, Sankaram MB. Topology of multivesicular liposomes, a model biliquid foam. Langmuir. 1996;12(20):4704\u20138. https:\/\/doi.org\/10.1021\/la960218s.","journal-title":"Langmuir"},{"key":"1223_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2015.11.021","volume":"221","author":"PP Wibroe","year":"2016","unstructured":"Wibroe PP, Ahmadvand D, Oghabian MA, Yaghmur A, Moghimi SM. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil\u00ae, Caelyx\u00ae, Doxorubicin, and SinaDoxosome. J Control Release. 2016;221:1\u20138. https:\/\/doi.org\/10.1016\/j.jconrel.2015.11.021.","journal-title":"J Control Release"},{"key":"1223_CR106","unstructured":"Doxil\u00ae - PSG. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/DoxorubicinHydrochloride_draft_Injectioninjeclipo_RLD50718_RC09\u201318.pdf. Accessed 30 Sept\u00a02021."},{"key":"1223_CR107","unstructured":"Bupivacaine \u2013 PSG. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Bupivacaine_liposomalinjectableinjection_NDA022496_RC11\u201317.pdf. Accessed 30 Sept\u00a02021."},{"issue":"2","key":"1223_CR108","doi-asserted-by":"publisher","first-page":"9","DOI":"10.22037\/ijpr.2020.112291.13663","volume":"19","author":"B Salehi","year":"2020","unstructured":"Salehi B, Mishra AP, Nigam M, et al. Multivesicular liposome (depofoam) in human diseases. Iran J Pharm Res IJPR. 2020;19(2):9\u201321. https:\/\/doi.org\/10.22037\/ijpr.2020.112291.13663.","journal-title":"Iran J Pharm Res IJPR"},{"issue":"1\u20132","key":"1223_CR109","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijpharm.2005.04.001","volume":"301","author":"H Zhong","year":"2005","unstructured":"Zhong H, Deng Y, Wang X, Yang B. Multivesicular liposome formulation for the sustained delivery of breviscapine. Int J Pharm. 2005;301(1\u20132):15\u201324. https:\/\/doi.org\/10.1016\/j.ijpharm.2005.04.001.","journal-title":"Int J Pharm"},{"key":"1223_CR110","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-021-01060-y","author":"C Akash","year":"2021","unstructured":"Akash C, Amruta G, Kanan P, Sumeet K, Kumar SA. A review on multivesicular liposomes for pharmaceutical applications: preparation, characterization, and translational challenges (In-Press). Drug Deliv Transl Res Published online. 2021. https:\/\/doi.org\/10.1007\/s13346-021-01060-y.","journal-title":"Drug Deliv Transl Res Published online"},{"key":"1223_CR111","unstructured":"Exparel (bupivacaine) liposomal injection - chemistry review. USFDA. \u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022496Orig1s000ChemR.pdf. Accessed 30 Sept\u00a02021."},{"key":"1223_CR112","doi-asserted-by":"crossref","unstructured":"Octreotide Acetate - PSG. USFDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Octreotideacetate_inj_21008_RV02\u201314.pdf. Accessed 30 Sept\u00a02021.","DOI":"10.1016\/S1359-6128(21)00176-2"},{"key":"1223_CR113","unstructured":"Prolixin Enanthate. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=016110. Accessed 30 Sept\u00a02021."},{"key":"1223_CR114","unstructured":"Prolixin Decanoate. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=016727. Accessed 30 Sept\u00a02021."},{"issue":"Suppl 1","key":"1223_CR115","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1089\/jam.1994.7.suppl_1.s-3","volume":"7","author":"P Edman","year":"1994","unstructured":"Edman P. Pharmaceutical formulations\u2013suspensions and solutions. J aerosol Med Off J Int Soc Aerosols Med. 1994;7(Suppl 1):S3-6. https:\/\/doi.org\/10.1089\/jam.1994.7.suppl_1.s-3.","journal-title":"J aerosol Med Off J Int Soc Aerosols Med"},{"key":"1223_CR116","unstructured":"Sterilization - Decision Tree - EMA. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/superseded-annex-note-guidance-development-pharmaceutics-decision-trees-selection-sterilisation_en.pdf. Accessed 4 May\u00a02022."},{"issue":"4","key":"1223_CR117","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1208\/s12249-010-9526-5","volume":"11","author":"K Hippalgaonkar","year":"2010","unstructured":"Hippalgaonkar K, Majumdar S, Kansara V. Injectable lipid emulsions-advancements, opportunities and challenges. AAPS PharmSciTech. 2010;11(4):1526\u201340. https:\/\/doi.org\/10.1208\/s12249-010-9526-5.","journal-title":"AAPS PharmSciTech"},{"key":"1223_CR118","unstructured":"Clevidipine - PSG. USFDA.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_022156.pdf. Accessed 30 Sept\u00a02021."},{"key":"1223_CR119","doi-asserted-by":"publisher","unstructured":"Agrawal H, Thacker N, Misra A. Parenteral delivery of peptides and proteins. First Edit. Elsevier Inc.\u00a02011. https:\/\/doi.org\/10.1016\/B978-0-12-384964-9.00011-6.","DOI":"10.1016\/B978-0-12-384964-9.00011-6"},{"issue":"3","key":"1223_CR120","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.anai.2019.06.005","volume":"123","author":"C Kessler","year":"2019","unstructured":"Kessler C, Edwards E, Dissinger E, Sye S, Visich T, Grant E. Usability and preference of epinephrine auto-injectors: Auvi-Q and EpiPen Jr. Ann Allergy, Asthma Immunol. 2019;123(3):256\u201362. https:\/\/doi.org\/10.1016\/j.anai.2019.06.005.","journal-title":"Ann Allergy, Asthma Immunol"},{"key":"1223_CR121","unstructured":"ISO 11040\u20138:2016(en) Prefilled syringes \u2014 Part 8: requirements and test methods for finished prefilled syringes. ISO.\u00a0https:\/\/www.iso.org\/obp\/ui\/#iso:std:iso:11040:-8:ed-1:v1:en. Accessed 30 Sept\u00a02021."},{"key":"1223_CR122","unstructured":"Guideline on the quality requirements for drug-device combinations. Eu Med Agency. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-quality-requirements-drug-device-combinations-first-version_en.pdf. Accessed 30 Sept\u00a02021.\u00a0"},{"key":"1223_CR123","unstructured":"Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products - Guidance for Industry and FDA Staff. USFDA. https:\/\/www.fda.gov\/media\/76403\/download. Accessed 30 Sept\u00a02021."},{"key":"1223_CR124","unstructured":"Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile. USFDA.\u00a0https:\/\/www.fda.gov\/media\/74445\/download. Accessed 30 Sept\u00a02021.\u00a0"},{"issue":"27","key":"1223_CR125","doi-asserted-by":"publisher","first-page":"12871","DOI":"10.1039\/C8NR02278J","volume":"10","author":"S Mourdikoudis","year":"2018","unstructured":"Mourdikoudis S, Pallares RM, Thanh NTK. Characterization techniques for nanoparticles: comparison and complementarity upon studying nanoparticle properties. Nanoscale. 2018;10(27):12871\u2013934. https:\/\/doi.org\/10.1039\/C8NR02278J.","journal-title":"Nanoscale"},{"key":"1223_CR126","doi-asserted-by":"publisher","unstructured":"Tomaszewska E, Soliwoda K, Kadziola K, et al. Detection limits of DLS and UV-Vis spectroscopy in characterization of polydisperse nanoparticles colloids. Yu WW, ed. J Nanomater. 2013;313081. https:\/\/doi.org\/10.1155\/2013\/313081.","DOI":"10.1155\/2013\/313081"},{"issue":"4","key":"1223_CR127","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/jbm.a.34053","volume":"100","author":"T-H Kim","year":"2012","unstructured":"Kim T-H, Kim M, Park H-S, Shin US, Gong M-S, Kim H-W. Size-dependent cellular toxicity of silver nanoparticles. J Biomed Mater Res A. 2012;100(4):1033\u201343. https:\/\/doi.org\/10.1002\/jbm.a.34053.","journal-title":"J Biomed Mater Res A"},{"key":"1223_CR128","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jconrel.2020.01.049","volume":"320","author":"J Parot","year":"2020","unstructured":"Parot J, Caputo F, Mehn D, Hackley VA, Calzolai L. Physical characterization of liposomal drug formulations using multi-detector asymmetrical-flow field flow fractionation. J Control Release. 2020;320:495\u2013510. https:\/\/doi.org\/10.1016\/j.jconrel.2020.01.049.","journal-title":"J Control Release"},{"key":"1223_CR129","doi-asserted-by":"publisher","unstructured":"Gupta S, Kesarla R, Chotai N, Misra A, Omri A. Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. Nazzal SM, ed. Biomed Res Int. 2017;5984014. https:\/\/doi.org\/10.1155\/2017\/5984014.","DOI":"10.1155\/2017\/5984014"},{"issue":"15","key":"1223_CR130","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1039\/C8AY00237A","volume":"10","author":"C Minelli","year":"2018","unstructured":"Minelli C, Sikora A, Garcia-Diez R, et al. Measuring the size and density of nanoparticles by centrifugal sedimentation and flotation. Anal Methods. 2018;10(15):1725\u201332. https:\/\/doi.org\/10.1039\/C8AY00237A.","journal-title":"Anal Methods"},{"issue":"5","key":"1223_CR131","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s11095-010-0073-2","volume":"27","author":"V Filipe","year":"2010","unstructured":"Filipe V, Hawe A, Jiskoot W. Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res. 2010;27(5):796\u2013810. https:\/\/doi.org\/10.1007\/s11095-010-0073-2.","journal-title":"Pharm Res"},{"issue":"42","key":"1223_CR132","doi-asserted-by":"publisher","first-page":"12545","DOI":"10.1021\/acs.langmuir.0c01079","volume":"36","author":"K Aburai","year":"2020","unstructured":"Aburai K, Hatanaka K, Takano S, Fujii S, Sakurai K. Characterizing an siRNA-containing lipid-nanoparticle prepared by a microfluidic reactor: small-angle X-ray scattering and cryotransmission electron microscopic studies. Langmuir. 2020;36(42):12545\u201354. https:\/\/doi.org\/10.1021\/acs.langmuir.0c01079.","journal-title":"Langmuir"},{"issue":"4","key":"1223_CR133","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00249-010-0661-4","volume":"40","author":"JM Freire","year":"2011","unstructured":"Freire JM, Domingues MM, Matos J, et al. Using zeta-potential measurements to quantify peptide partition to lipid membranes. Eur Biophys J. 2011;40(4):481\u20137. https:\/\/doi.org\/10.1007\/s00249-010-0661-4.","journal-title":"Eur Biophys J"},{"issue":"1","key":"1223_CR134","doi-asserted-by":"publisher","first-page":"17479","DOI":"10.1038\/s41598-017-14981-x","volume":"7","author":"R Vogel","year":"2017","unstructured":"Vogel R, Pal AK, Jambhrunkar S, et al. High-resolution single particle zeta potential characterisation of biological nanoparticles using tunable resistive pulse sensing. Sci Rep. 2017;7(1):17479. https:\/\/doi.org\/10.1038\/s41598-017-14981-x.","journal-title":"Sci Rep"},{"issue":"6","key":"1223_CR135","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1021\/nn5014484","volume":"8","author":"S-S Kim","year":"2014","unstructured":"Kim S-S, Rait A, Kim E, et al. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano. 2014;8(6):5494\u2013514. https:\/\/doi.org\/10.1021\/nn5014484.","journal-title":"ACS Nano"},{"key":"1223_CR136","doi-asserted-by":"publisher","unstructured":"Bushell M, Beauchemin S, Kunc F, et al. Characterization of commercial metal oxide nanomaterials: crystalline phase, particle size and specific surface area. Nanomaterials. 2020;10(9). https:\/\/doi.org\/10.3390\/nano10091812.","DOI":"10.3390\/nano10091812"},{"issue":"10\u201311","key":"1223_CR137","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/sia.5378","volume":"46","author":"S Rades","year":"2014","unstructured":"Rades S, Wirth T, Unger W. Investigation of silica nanoparticles by Auger electron spectroscopy (AES). Surf Interface Anal. 2014;46(10\u201311):952\u20136. https:\/\/doi.org\/10.1002\/sia.5378.","journal-title":"Surf Interface Anal"},{"issue":"8","key":"1223_CR138","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s13204-017-0634-3","volume":"7","author":"V Dave","year":"2017","unstructured":"Dave V, Sharma S, Yadav RB, Agarwal U. Herbal liposome for the topical delivery of ketoconazole for the effective treatment of seborrheic dermatitis. Appl Nanosci. 2017;7(8):973\u201387. https:\/\/doi.org\/10.1007\/s13204-017-0634-3.","journal-title":"Appl Nanosci"},{"issue":"2","key":"1223_CR139","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jsps.2011.10.001","volume":"20","author":"RGS Maheshwari","year":"2012","unstructured":"Maheshwari RGS, Tekade RK, Sharma PA, et al. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc. 2012;20(2):161\u201370. https:\/\/doi.org\/10.1016\/j.jsps.2011.10.001.","journal-title":"Saudi Pharm J SPJ Off Publ Saudi Pharm Soc"},{"issue":"1","key":"1223_CR140","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0939-6411(02)00130-3","volume":"55","author":"MA Schubert","year":"2003","unstructured":"Schubert MA, M\u00fcller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles \u2013 evaluation of the method and process parameters. Eur J Pharm Biopharm. 2003;55(1):125\u201331. https:\/\/doi.org\/10.1016\/S0939-6411(02)00130-3.","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"1223_CR141","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1021\/am2004366","volume":"3","author":"L Beqa","year":"2011","unstructured":"Beqa L, Fan Z, Singh AK, Senapati D, Ray PC. Gold nano-popcorn attached SWCNT hybrid nanomaterial for targeted diagnosis and photothermal therapy of human breast cancer cells. ACS Appl Mater Interfaces. 2011;3(9):3316\u201324. https:\/\/doi.org\/10.1021\/am2004366.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1223_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultramic.2015.04.014","author":"P Felfer","year":"2015","unstructured":"Felfer P, Li T, Eder K, et al. New approaches to nanoparticle sample fabrication for atom probe tomography. Ultramicroscopy Published online. 2015. https:\/\/doi.org\/10.1016\/j.ultramic.2015.04.014.","journal-title":"Ultramicroscopy Published online"},{"issue":"7","key":"1223_CR143","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1080\/03639045.2020.1775632","volume":"46","author":"SB Routray","year":"2020","unstructured":"Routray SB, Patra CN, Raju R, Panigrahi KC, Jena GK. Lyophilized SLN of Cinnacalcet HCl: BBD enabled optimization, characterization and pharmacokinetic study. Drug Dev Ind Pharm. 2020;46(7):1080\u201391. https:\/\/doi.org\/10.1080\/03639045.2020.1775632.","journal-title":"Drug Dev Ind Pharm"},{"key":"1223_CR144","first-page":"6","volume":"660\u201361","author":"JV Marques Zoccal","year":"2010","unstructured":"Marques Zoccal JV, de Oliveira AF, Silveira Goncalves JA. S\u00edntesis y caracterizaci\u00f3n de nanopart\u00edculas de TiO2 por el m\u00e9todo Pechini. Mater Sci Forum. 2010;660\u201361:6.","journal-title":"Mater Sci Forum"},{"issue":"60","key":"1223_CR145","doi-asserted-by":"publisher","first-page":"34634","DOI":"10.1039\/C8RA07601D","volume":"8","author":"GM Shashidhar","year":"2018","unstructured":"Shashidhar GM, Manohar B. Nanocharacterization of liposomes for the encapsulation of water soluble compounds from Cordyceps sinensis CS1197 by a supercritical gas anti-solvent technique. RSC Adv. 2018;8(60):34634\u201349. https:\/\/doi.org\/10.1039\/C8RA07601D.","journal-title":"RSC Adv"},{"key":"1223_CR146","doi-asserted-by":"publisher","unstructured":"Villasmil-S\u00e1nchez S, Rabasco AM, Gonz\u00e1lez-Rodr\u00edguez ML. Thermal and 31P-NMR studies to elucidate sumatriptan succinate entrapment behavior in Phosphatidylcholine\/Cholesterol liposomes. Comparative 31P-NMR analysis on negatively and positively-charged liposomes. Colloids Surfaces B Biointerfaces. 2013;105:14\u201323. https:\/\/doi.org\/10.1016\/j.colsurfb.2012.12.019.","DOI":"10.1016\/j.colsurfb.2012.12.019"},{"key":"1223_CR147","doi-asserted-by":"crossref","unstructured":"Oswald M, Platscher M, Geissler S, Goepferich A. HPLC analysis as a tool for assessing targeted liposome composition. Int J Pharm. 2015;497(1\u20132):293\u2013300. https:\/\/www.unboundmedicine.com\/medline\/citation\/26570988\/HPLC_analysis_as_a_tool_for_assessing_targeted_liposome_composition_.","DOI":"10.1016\/j.ijpharm.2015.11.014"},{"issue":"3","key":"1223_CR148","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1208\/aapsj060323","volume":"6","author":"LH Reddy","year":"2004","unstructured":"Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RR. Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. AAPS J. 2004;6(3):55\u201364. https:\/\/doi.org\/10.1208\/aapsj060323.","journal-title":"AAPS J"},{"key":"1223_CR149","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2019.09.016","volume":"315","author":"M Yu","year":"2019","unstructured":"Yu M, Yuan W, Li D, Schwendeman A, Schwendeman SP. Predicting drug release kinetics from nanocarriers inside dialysis bags. J Control Release. 2019;315:23\u201330. https:\/\/doi.org\/10.1016\/j.jconrel.2019.09.016.","journal-title":"J Control Release"},{"key":"1223_CR150","unstructured":"FDA. Dissolution methods database. FDA 2016. Published online 2010. www.accessdata.fda.gov\/scripts\/cder\/dissolution\/dsp_SearchResults.cfm."},{"issue":"5","key":"1223_CR151","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3109\/02652049509006783","volume":"12","author":"X Armengol","year":"1995","unstructured":"Armengol X, Estelrich J. Physical stability of different liposome compositions obtained by extrusion method. J Microencapsul. 1995;12(5):525\u201335. https:\/\/doi.org\/10.3109\/02652049509006783.","journal-title":"J Microencapsul"},{"issue":"4","key":"1223_CR152","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1208\/s12248-008-9061-4","volume":"10","author":"F Kesisoglou","year":"2008","unstructured":"Kesisoglou F, Wu Y. Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J. 2008;10(4):516\u201325. https:\/\/doi.org\/10.1208\/s12248-008-9061-4.","journal-title":"AAPS J"},{"issue":"1","key":"1223_CR153","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0378-5173(01)00721-9","volume":"223","author":"N Berger","year":"2001","unstructured":"Berger N, Sachse A, Bender J, Schubert R, Brandl M. Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. Int J Pharm. 2001;223(1):55\u201368. https:\/\/doi.org\/10.1016\/S0378-5173(01)00721-9.","journal-title":"Int J Pharm"},{"issue":"1","key":"1223_CR154","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejps.2005.01.020","volume":"25","author":"B Ruozi","year":"2005","unstructured":"Ruozi B, Tosi G, Forni F, Fresta M, Vandelli MA. Atomic force microscopy and photon correlation spectroscopy: two techniques for rapid characterization of liposomes. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2005;25(1):81\u20139. https:\/\/doi.org\/10.1016\/j.ejps.2005.01.020.","journal-title":"Eur J Pharm Sci Off J Eur Fed Pharm Sci"},{"key":"1223_CR155","doi-asserted-by":"publisher","first-page":"12168","DOI":"10.1088\/1742-6596\/1410\/1\/012168","volume":"1410","author":"I Kolokolnikov","year":"2019","unstructured":"Kolokolnikov I, Nepomnyashchaya E, Velichko E. Static light scattering for determination of physical parameters of macro- and nanoparticles. J Phys Conf Ser. 2019;1410:12168. https:\/\/doi.org\/10.1088\/1742-6596\/1410\/1\/012168.","journal-title":"J Phys Conf Ser"},{"key":"1223_CR156","doi-asserted-by":"publisher","unstructured":"Shah R, Eldridge D, Palombo E, Harding I. Characterization. In: Lipid Nanoparticles: Production, Characterization and Stability. Springer International Publishing.\u00a02015;45\u201374.\u00a0https:\/\/doi.org\/10.1007\/978-3-319-10711-0_4.","DOI":"10.1007\/978-3-319-10711-0_4"},{"issue":"5","key":"1223_CR157","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.talanta.2005.08.031","volume":"68","author":"KA Edwards","year":"2006","unstructured":"Edwards KA, Baeumner AJ. Analysis of liposomes. Talanta. 2006;68(5):1432\u201341. https:\/\/doi.org\/10.1016\/j.talanta.2005.08.031.","journal-title":"Talanta"},{"key":"1223_CR158","doi-asserted-by":"crossref","unstructured":"Preparation, Characterization and applications of liposomes: state of the art. J Colloid Sci Biotechnol. 2012;1(2).","DOI":"10.1166\/jcsb.2012.1020"},{"issue":"6","key":"1223_CR159","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1016\/S0006-3495(96)79517-6","volume":"71","author":"K Akashi","year":"1996","unstructured":"Akashi K, Miyata H, Itoh H, Kinosita KJ. Preparation of giant liposomes in physiological conditions and their characterization under an optical microscope. Biophys J. 1996;71(6):3242\u201350. https:\/\/doi.org\/10.1016\/S0006-3495(96)79517-6.","journal-title":"Biophys J"},{"key":"1223_CR160","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.micron.2017.03.019","volume":"99","author":"J Asadi","year":"2017","unstructured":"Asadi J, Ferguson S, Raja H, et al. Enhanced imaging of lipid rich nanoparticles embedded in methylcellulose films for transmission electron microscopy using mixtures of heavy metals. Micron. 2017;99:40\u20138. https:\/\/doi.org\/10.1016\/j.micron.2017.03.019.","journal-title":"Micron"},{"issue":"1","key":"1223_CR161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-5729(99)00003-5","volume":"34","author":"B Cappella","year":"1999","unstructured":"Cappella B, Dietler G. Force-distance curves by atomic force microscopy. Surf Sci Rep. 1999;34(1):1\u2013104. https:\/\/doi.org\/10.1016\/S0167-5729(99)00003-5.","journal-title":"Surf Sci Rep"},{"issue":"1","key":"1223_CR162","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1038\/s41598-019-38915-x","volume":"9","author":"A Kim","year":"2019","unstructured":"Kim A, Ng WB, Bernt W, Cho N-J. Validation of size estimation of nanoparticle tracking analysis on polydisperse macromolecule assembly. Sci Rep. 2019;9(1):2639. https:\/\/doi.org\/10.1038\/s41598-019-38915-x.","journal-title":"Sci Rep"},{"issue":"2","key":"1223_CR163","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jcis.2010.09.006","volume":"352","author":"H Saveyn","year":"2010","unstructured":"Saveyn H, De Baets B, Thas O, Hole P, Smith J, Van der Meeren P. Accurate particle size distribution determination by nanoparticle tracking analysis based on 2-D Brownian dynamics simulation. J Colloid Interface Sci. 2010;352(2):593\u2013600. https:\/\/doi.org\/10.1016\/j.jcis.2010.09.006.","journal-title":"J Colloid Interface Sci"},{"key":"1223_CR164","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.crstbi.2020.08.004","volume":"2","author":"S Da Vela","year":"2020","unstructured":"Da Vela S, Svergun DI. Methods, development and applications of small-angle X-ray scattering to characterize biological macromolecules in solution. Curr Res Struct Biol. 2020;2:164\u201370. https:\/\/doi.org\/10.1016\/j.crstbi.2020.08.004.","journal-title":"Curr Res Struct Biol"},{"key":"1223_CR165","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1088\/1742-6596\/1134\/1\/012007","volume":"1134","author":"DI Belenkii","year":"2018","unstructured":"Belenkii DI, Magomedov TM. Nanoparticle size and zeta potential express analysis in initial material\u2019s control at the enterprises of powder industry. J Phys Conf Ser. 2018;1134:12007. https:\/\/doi.org\/10.1088\/1742-6596\/1134\/1\/012007.","journal-title":"J Phys Conf Ser"},{"issue":"4","key":"1223_CR166","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0955-2219(98)00208-8","volume":"19","author":"R Greenwood","year":"1999","unstructured":"Greenwood R, Kendall K. Selection of suitable dispersants for aqueous suspensions of zirconia and titania powders using acoustophoresis. J Eur Ceram Soc. 1999;19(4):479\u201388. https:\/\/doi.org\/10.1016\/S0955-2219(98)00208-8.","journal-title":"J Eur Ceram Soc"},{"issue":"9","key":"1223_CR167","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00706-017-1994-9","volume":"148","author":"M Kan\u00e1sov\u00e1","year":"2017","unstructured":"Kan\u00e1sov\u00e1 M, Nesm\u011br\u00e1k K. Systematic review of liposomes\u2019 characterization methods. Monatshefte f\u00fcr Chemie - Chem Mon. 2017;148(9):1581\u201393. https:\/\/doi.org\/10.1007\/s00706-017-1994-9.","journal-title":"Monatshefte f\u00fcr Chemie - Chem Mon"},{"key":"1223_CR168","doi-asserted-by":"publisher","unstructured":"Bunaciu AA, Udri\u015ftioiu E gabriela, Aboul-Enein HY. X-ray diffraction: instrumentation and applications. Crit Rev Anal Chem. 2015;45(4):289\u2013299.\u00a0https:\/\/doi.org\/10.1080\/10408347.2014.949616.","DOI":"10.1080\/10408347.2014.949616"},{"key":"1223_CR169","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0165-9936(02)01208-6","volume":"21","author":"T Vankeirsbilck","year":"2002","unstructured":"Vankeirsbilck T, Vercauteren A, Baeyens W, et al. Applications of Raman spectroscopy in pharmaceutical analysis. TrAC Trends Anal Chem. 2002;21:869\u201377. https:\/\/doi.org\/10.1016\/S0165-9936(02)01208-6.","journal-title":"TrAC Trends Anal Chem"},{"issue":"7","key":"1223_CR170","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1208\/s12249-018-1135-8","volume":"19","author":"W Wang","year":"2018","unstructured":"Wang W, Zhang H, Yuan Y, Guo Y, He S. Research progress of Raman spectroscopy in drug analysis. AAPS PharmSciTech. 2018;19(7):2921\u20138. https:\/\/doi.org\/10.1208\/s12249-018-1135-8.","journal-title":"AAPS PharmSciTech"},{"issue":"1\u20132","key":"1223_CR171","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijpharm.2011.01.038","volume":"417","author":"MAA O\u2019Neill","year":"2011","unstructured":"O\u2019Neill MAA, Gaisford S. Application and use of isothermal calorimetry in pharmaceutical development. Int J Pharm. 2011;417(1\u20132):83\u201393. https:\/\/doi.org\/10.1016\/j.ijpharm.2011.01.038.","journal-title":"Int J Pharm"},{"key":"1223_CR172","doi-asserted-by":"publisher","unstructured":"Mansfield E6. Recent advances in thermal analysis of nanoparticles: methods, models and kinetics*. In: Tewary VK, Zhang Y, eds. Modeling, Characterization, and Production of Nanomaterials. Woodhead Publishing Series in Electronic and Optical Materials. Woodhead Publishing. 2015;167\u2013178. https:\/\/doi.org\/10.1016\/B978-1-78242-228-0.00006-5.","DOI":"10.1016\/B978-1-78242-228-0.00006-5"},{"issue":"1053","key":"1223_CR173","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1039\/AN9638800906","volume":"88","author":"AW Coats","year":"1963","unstructured":"Coats AW, Redfern JP. Thermogravimetric analysis. A review Analyst. 1963;88(1053):906\u201324. https:\/\/doi.org\/10.1039\/AN9638800906.","journal-title":"A review Analyst"},{"issue":"1","key":"1223_CR174","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/s0009-3084(00)00220-6","volume":"109","author":"M Fr\u00f6hlich","year":"2001","unstructured":"Fr\u00f6hlich M, Brecht V, Peschka-S\u00fcss R. Parameters influencing the determination of liposome lamellarity by 31P-NMR. Chem Phys Lipids. 2001;109(1):103\u201312. https:\/\/doi.org\/10.1016\/s0009-3084(00)00220-6.","journal-title":"Chem Phys Lipids"},{"key":"1223_CR175","first-page":"945","volume":"2","author":"H Anwekar","year":"2011","unstructured":"Anwekar H, Patel S, Singhai A. Liposome-as drug carriers. Int J Pharm Life Sci. 2011;2:945\u201351.","journal-title":"Int J Pharm Life Sci"},{"issue":"6","key":"1223_CR176","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/BF00160401","volume":"39","author":"I Baeza","year":"1994","unstructured":"Baeza I, Wong C, Mondrag\u00f3n R, et al. Transbilayer diffusion of divalent cations into liposomes mediated by lipidic particles of phosphatidate. J Mol Evol. 1994;39(6):560\u20138. https:\/\/doi.org\/10.1007\/BF00160401.","journal-title":"J Mol Evol"},{"issue":"11","key":"1223_CR177","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/BF02269744","volume":"30","author":"HP Nissen","year":"1990","unstructured":"Nissen HP, Kreysel HW. The use of HPLC for the determination of lipids in biological materials. Chromatographia. 1990;30(11):686\u201390. https:\/\/doi.org\/10.1007\/BF02269744.","journal-title":"Chromatographia"},{"key":"1223_CR178","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-1-62703-487-6_2","volume":"1033","author":"RM Deranieh","year":"2013","unstructured":"Deranieh RM, Joshi AS, Greenberg ML. Thin-layer chromatography of phospholipids. Methods Mol Biol. 2013;1033:21\u20137. https:\/\/doi.org\/10.1007\/978-1-62703-487-6_2.","journal-title":"Methods Mol Biol"},{"key":"1223_CR179","unstructured":"In vitro drug release methods for liposomal drug delivery systems. Express Pharma. https:\/\/www.expresspharma.in\/in-vitro-drug-release-methods-for-liposomal-drug-delivery-systems\/. Accessed 30 Sept\u00a02021"},{"issue":"6","key":"1223_CR180","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3109\/02652049709006824","volume":"14","author":"ZM Mathir","year":"1997","unstructured":"Mathir ZM, Dangor CM, Govender T, Chetty DJ. In vitro characterization of a controlled-release chlorpheniramine maleate delivery system prepared by the air-suspension technique. J Microencapsul. 1997;14(6):743\u201351. https:\/\/doi.org\/10.3109\/02652049709006824.","journal-title":"J Microencapsul"},{"issue":"3","key":"1223_CR181","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1021\/acsomega.7b01235","volume":"3","author":"X Wei","year":"2018","unstructured":"Wei X, Shamrakov D, Nudelman S, et al. Cardinal role of intraliposome doxorubicin-sulfate nanorod crystal in doxil properties and performance. ACS Omega. 2018;3(3):2508\u201317. https:\/\/doi.org\/10.1021\/acsomega.7b01235.","journal-title":"ACS Omega"},{"key":"1223_CR182","doi-asserted-by":"publisher","unstructured":"Vinchhi P, Patel JK, Patel MM. High-pressure homogenization techniques for nanoparticles BT - emerging technologies for nanoparticle manufacturing. In: Patel JK, Pathak Y V, eds. Springer International Publishing.\u00a02021;263\u2013285. https:\/\/doi.org\/10.1007\/978-3-030-50703-9_11.","DOI":"10.1007\/978-3-030-50703-9_11"},{"key":"1223_CR183","doi-asserted-by":"publisher","unstructured":"AU - Thomson LM, AU - Polizzotti BD, AU - McGowan FX, AU - Kheir JN. Manufacture of concentrated, lipid-based oxygen microbubble emulsions by high shear homogenization and serial concentration. JoVE. 2014;(87):e51467. https:\/\/doi.org\/10.3791\/51467.","DOI":"10.3791\/51467"},{"key":"1223_CR184","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-1-60761-609-2_14","volume":"624","author":"G Niu","year":"2010","unstructured":"Niu G, Cogburn B, Hughes J. Preparation and characterization of doxorubicin liposomes. Methods Mol Biol. 2010;624:211\u20139. https:\/\/doi.org\/10.1007\/978-1-60761-609-2_14.","journal-title":"Methods Mol Biol"},{"key":"1223_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120455","volume":"599","author":"\u00c1 C\u00e1rcamo-Mart\u00ednez","year":"2021","unstructured":"C\u00e1rcamo-Mart\u00ednez \u00c1, Mallon B, Dom\u00ednguez-Robles J, Vora LK, Anjani QK, Donnelly RF. Hollow microneedles: a perspective in biomedical applications. Int J Pharm. 2021;599: 120455. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120455.","journal-title":"Int J Pharm"},{"key":"1223_CR186","unstructured":"Complex Injectable Market. Persistence market research. https:\/\/www.persistencemarketresearch.com\/market-research\/complex-injectable-market.asp. Accessed 30 Sept\u00a02021."},{"key":"1223_CR187","doi-asserted-by":"publisher","unstructured":"Pandey A, Singh D, Dhas N, et al. Chapter 8 - complex injectables: development, delivery, and advancement. In: Shegokar R, ed. Delivery of Drugs. Elsevier.\u00a02020;191\u2013213. https:\/\/doi.org\/10.1016\/B978-0-12-817776-1.00008-0.","DOI":"10.1016\/B978-0-12-817776-1.00008-0"},{"key":"1223_CR188","unstructured":"Liposome Drug Products - Guidance for Industry. USFDA. https:\/\/www.fda.gov\/media\/70837\/download.\u00a0Accessed 30 Sept 2021."},{"issue":"1","key":"1223_CR189","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1556-276X-8-102","volume":"8","author":"A Akbarzadeh","year":"2013","unstructured":"Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. https:\/\/doi.org\/10.1186\/1556-276X-8-102.","journal-title":"Nanoscale Res Lett"},{"issue":"23\u201324","key":"1223_CR190","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1016\/j.biomaterials.2009.04.009","volume":"30","author":"N Singh","year":"2009","unstructured":"Singh N, Manshian B, Jenkins GJS, et al. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials. 2009;30(23\u201324):3891\u2013914. https:\/\/doi.org\/10.1016\/j.biomaterials.2009.04.009.","journal-title":"Biomaterials"},{"issue":"13","key":"1223_CR191","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.addr.2012.08.005","volume":"64","author":"X-Q Zhang","year":"2012","unstructured":"Zhang X-Q, Xu X, Bertrand N, Pridgen E, Swami A, Farokhzad OC. Interactions of nanomaterials and biological systems: implications to personalized nanomedicine. Adv Drug Deliv Rev. 2012;64(13):1363\u201384. https:\/\/doi.org\/10.1016\/j.addr.2012.08.005.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01223-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-022-01223-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01223-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:18:21Z","timestamp":1744190301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-022-01223-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,14]]},"references-count":191,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1223"],"URL":"https:\/\/doi.org\/10.1007\/s13346-022-01223-5","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,14]]},"assertion":[{"value":"3 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}